Matches in SemOpenAlex for { <https://semopenalex.org/work/W3203896279> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W3203896279 endingPage "S571" @default.
- W3203896279 startingPage "S571" @default.
- W3203896279 abstract "Bevacizumab-based chemotherapy is the recommended first-line therapeutic strategy for metastatic colorectal cancer (mCRC). Yet, some patients do not benefit from this association and until now robust predictive or prognostic biomarker with clinical practice applicability have not been identified. Serum analysis by mid-infrared spectroscopy (SMIRS) allows a rapid and non-invasive metabolomic profiling of an individual. Its prognostic value has never been assessed in mCRC. The aim of this study was to evaluate the prognostic yield of SMIRS in patients receiving first-line bevacizumab-based treatment for mCRC. We conducted an ancillary analysis from a multicentre prospective study (NCT00489697). All baseline serums were screened by attenuated total reflection method. Principal component analysis and unsupervised k-mean partitioning methods were performed blinded to all patients’ data. Endpoints were progression-free survival (PFS) and overall survival (OS). From the 108 included patients, two prognostic groups defined by spectral signatures were blindly discriminated by SMIRS. First group patients (n = 25) had lower body mass index (p = 0.026) and albumin levels (p < 0.001). They had higher levels of angiopoietin-2, vascular endothelial growth factor, lactate dehydrogenase and carcinoembryonic antigen (p < 0.001 for all). Their spectral signature differed according to six significative absorption bands corresponding to lipid deficiency and different sugar and protein composition. They had less grade 1-2 bevacizumab-related toxicity (p = 0.041). Their best objective response rate was worse: 52.0% vs 73.5% (p = 0.043). In univariate analysis, their OS and PFS were shorter with respective medians: 17.6 vs 27.9 months (p = 0.02) and 8.7 vs 11.3 months (p = 0.03). In multivariate analysis, PFS was significantly shorter (HR: 1.74, 95% CI [1.07-2.82], p = 0.025) with a similar trend for OS (HR: 1.69, 95% CI [0.98-2.93], p = 0.061). By metabolomic fingerprinting, SMIRS on baseline serum proves to be a promising prognostic tool for patients receiving first-line bevacizumab-based chemotherapy for mCRC." @default.
- W3203896279 created "2021-10-11" @default.
- W3203896279 creator A5001067418 @default.
- W3203896279 creator A5001479918 @default.
- W3203896279 creator A5001817941 @default.
- W3203896279 creator A5022288769 @default.
- W3203896279 creator A5024027732 @default.
- W3203896279 creator A5025502682 @default.
- W3203896279 creator A5031132493 @default.
- W3203896279 creator A5032731284 @default.
- W3203896279 creator A5036691397 @default.
- W3203896279 creator A5066354699 @default.
- W3203896279 creator A5068409134 @default.
- W3203896279 creator A5076878654 @default.
- W3203896279 creator A5077000250 @default.
- W3203896279 creator A5084430346 @default.
- W3203896279 creator A5084815041 @default.
- W3203896279 creator A5088540864 @default.
- W3203896279 creator A5089555619 @default.
- W3203896279 date "2021-09-01" @default.
- W3203896279 modified "2023-10-18" @default.
- W3203896279 title "481P Evaluation of serum mid-infrared spectroscopy as new prognostic marker for bevacizumab-based chemotherapy in first-line treatment of metastatic colorectal cancer" @default.
- W3203896279 doi "https://doi.org/10.1016/j.annonc.2021.08.1002" @default.
- W3203896279 hasPublicationYear "2021" @default.
- W3203896279 type Work @default.
- W3203896279 sameAs 3203896279 @default.
- W3203896279 citedByCount "0" @default.
- W3203896279 crossrefType "journal-article" @default.
- W3203896279 hasAuthorship W3203896279A5001067418 @default.
- W3203896279 hasAuthorship W3203896279A5001479918 @default.
- W3203896279 hasAuthorship W3203896279A5001817941 @default.
- W3203896279 hasAuthorship W3203896279A5022288769 @default.
- W3203896279 hasAuthorship W3203896279A5024027732 @default.
- W3203896279 hasAuthorship W3203896279A5025502682 @default.
- W3203896279 hasAuthorship W3203896279A5031132493 @default.
- W3203896279 hasAuthorship W3203896279A5032731284 @default.
- W3203896279 hasAuthorship W3203896279A5036691397 @default.
- W3203896279 hasAuthorship W3203896279A5066354699 @default.
- W3203896279 hasAuthorship W3203896279A5068409134 @default.
- W3203896279 hasAuthorship W3203896279A5076878654 @default.
- W3203896279 hasAuthorship W3203896279A5077000250 @default.
- W3203896279 hasAuthorship W3203896279A5084430346 @default.
- W3203896279 hasAuthorship W3203896279A5084815041 @default.
- W3203896279 hasAuthorship W3203896279A5088540864 @default.
- W3203896279 hasAuthorship W3203896279A5089555619 @default.
- W3203896279 hasBestOaLocation W32038962791 @default.
- W3203896279 hasConcept C121608353 @default.
- W3203896279 hasConcept C126322002 @default.
- W3203896279 hasConcept C143998085 @default.
- W3203896279 hasConcept C185592680 @default.
- W3203896279 hasConcept C2776694085 @default.
- W3203896279 hasConcept C2777802072 @default.
- W3203896279 hasConcept C2781197716 @default.
- W3203896279 hasConcept C526805850 @default.
- W3203896279 hasConcept C55493867 @default.
- W3203896279 hasConcept C71924100 @default.
- W3203896279 hasConceptScore W3203896279C121608353 @default.
- W3203896279 hasConceptScore W3203896279C126322002 @default.
- W3203896279 hasConceptScore W3203896279C143998085 @default.
- W3203896279 hasConceptScore W3203896279C185592680 @default.
- W3203896279 hasConceptScore W3203896279C2776694085 @default.
- W3203896279 hasConceptScore W3203896279C2777802072 @default.
- W3203896279 hasConceptScore W3203896279C2781197716 @default.
- W3203896279 hasConceptScore W3203896279C526805850 @default.
- W3203896279 hasConceptScore W3203896279C55493867 @default.
- W3203896279 hasConceptScore W3203896279C71924100 @default.
- W3203896279 hasLocation W32038962791 @default.
- W3203896279 hasOpenAccess W3203896279 @default.
- W3203896279 hasPrimaryLocation W32038962791 @default.
- W3203896279 hasRelatedWork W2067097538 @default.
- W3203896279 hasRelatedWork W2077615248 @default.
- W3203896279 hasRelatedWork W2114024295 @default.
- W3203896279 hasRelatedWork W2302472031 @default.
- W3203896279 hasRelatedWork W2326197106 @default.
- W3203896279 hasRelatedWork W2339289555 @default.
- W3203896279 hasRelatedWork W2345567628 @default.
- W3203896279 hasRelatedWork W2755443795 @default.
- W3203896279 hasRelatedWork W2914832607 @default.
- W3203896279 hasRelatedWork W3203896279 @default.
- W3203896279 hasVolume "32" @default.
- W3203896279 isParatext "false" @default.
- W3203896279 isRetracted "false" @default.
- W3203896279 magId "3203896279" @default.
- W3203896279 workType "article" @default.